NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Mkt Cap: US$416.0m

NGM Biopharmaceuticals Financial Health

How is NGM Biopharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NGM's short term assets ($315.7M) exceed its short term liabilities ($48.6M).

Long Term Liabilities: NGM's short term assets ($315.7M) exceed its long term liabilities ($1.4M).

Debt to Equity History and Analysis

Debt Level: NGM is debt free.

Reducing Debt: NGM has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NGM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NGM has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 35.7% each year

Discover healthy companies